Evaluation of Pharmacodynamic Effects of Intratumoral Delivery of Plasmid IL-12 Electroporation in Patients With Triple Negative Breast Cancer

Trial Profile

Evaluation of Pharmacodynamic Effects of Intratumoral Delivery of Plasmid IL-12 Electroporation in Patients With Triple Negative Breast Cancer

Recruiting
Phase of Trial: Phase II

Latest Information Update: 16 Dec 2016

At a glance

  • Drugs Tavokinogene telsaplasmid (Primary)
  • Indications Advanced breast cancer
  • Focus Biomarker; Pharmacogenomic; Therapeutic Use
  • Sponsors OncoSec Medical
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 12 Dec 2016 Planned primary completion date changed from 1 Oct 2016 to 1 Mar 2017.
    • 03 Sep 2015 Status changed from not yet recruiting to recruiting, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top